The Squamous Cell Carcinoma Market to Reach USD 1,469.0 Million by 2035, Impelled by Advancements in Targeted Therapies

Squamous Cell Carcinoma Market Outlook 2025-2035:

The 7 major squamous cell carcinoma markets reached a value of USD 739.1 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,469.0 Million by 2035, exhibiting a growth rate (CAGR) of 6.43% during 2025-2035. The Squamous Cell Carcinoma (SCC) market is being driven by the increasing adoption of non-invasive and minimally invasive treatment options, such as photodynamic therapy (PDT), laser treatments, and cryotherapy, which offer effective tumor control while minimizing scarring and recovery time. Advanced therapy is specifically effective for localized SCC lesions and with an improvement of cosmetic effects and reduction of aggressive surgical procedures. Early SCC lesions can also be treated less invasively with reduced side effects and faster recovery time, having made early SCC treatments more efficient. These treatments gain popularity among patients looking for convenience. Additionally, these approaches have a short post-treatment care period, which makes them more appealing to patients with limited access to complex healthcare settings or to those looking for immediate solutions.

Advances in Early Detection and Diagnostic Technologies: Driving the Squamous Cell Carcinoma Market 

Modern diagnostic and treatment technologies are transforming the Squamous Cell Carcinoma (SCC) market, significantly improving patient management and outcomes. Contemporary imaging technologies are taking advantage of the benefits of underused film-based systems such as dermoscopy and high-resolution photography to facilitate visualization of SCC lesions, which is central to the accuracy of both treatment planning and diagnosis. Molecular testing like PCR and NGS are being applied more and more for the identification of genetic mutation and risk stratification with respect to high-risk mutations in SCC, thereby helping more personalized therapeutic strategies. AI-based imaging modalities further optimize diagnostic accuracy, but even these help in classification, grading, and tracking improvement in SCC, thus reducing subjective interpretation to a great extent. Close to non-invasive modalities like cutting-edge laser treatments, photodynamic therapy (PDT), and topical treatments are other management alternatives for early-stage SCC with minimal or no downtime with fewer complications. This is representative of controllable options for the patients to manage such tumors without surgery. Also under development are new wearables like smart patches to enable real-time monitoring of the skin and maximize the delivery of these therapies to optimize personalized care in underserved areas with limited access to specialized care. Telemedicine platforms also increase access to dermatologic care with the delivery of consultations, diagnoses, and treatment advice, all remotely. These are enhancing the accessibility of treatment and minimizing the risks involved as well as improving patient outcomes in the long term for SCC patients.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The squamous cell carcinoma market is experiencing remarkable market growth due to the introduction of newly revolutionized and updated pharmacological therapies. Novel systemic and topical agents are being developed to mechanistically target the pathways involved in squamous cell carcinomas, focusing mainly on the more resistant strains of cancers. These monoclonal antibodies are specifically directed at the cytokines produced during the inflammatory activities contributing to tumor growth or driving the internal mechanisms forming squamous cell carcinomas. The development of drug delivery technology, such as the incorporation of liposomes, hydrogels, and carriers based on nanotechnology, allows targeted treatment at the site of the tumor due to high doses of localized treatment and minimal systemic side effects, thus having better overall efficacy. Research on biologics is also rapidly spreading for chronic inflammatory diseases associated with SCC. Since 2010, monoclonal antibodies to pro-inflammatory cytokines such as interleukin-17 and interleukin-1 have shown applications in reducing tumor growth by targeting inflammatory processes and the mechanisms underlying squamous cell carcinoma formation. Along with conventional therapies, focus is shifted toward co-therapies such as probiotics and immunomodulators to the natural defense restoration to ameliorate the skin microbes' balance toward SCC recurrence prevention. Targeted combination approaches, including immunotherapies with chemotherapy and targeted agents, are gaining increasing use for treating the multi-faceted nature of SCC pathophysiology. Advancing toward more patient-centered approaches in their therapies, all of these are ultimately gearing toward achieving better outcomes among patients who live with SCC. Biofilm-disrupting agents and emerging topical formulations are additional emerging solutions for patients as they make treatment less complicated and much easier.

Marketed Therapies in Squamous Cell Carcinoma Market

Libtayo (Cemiplimab): Regeneron Pharmaceuticals

Libtayo (cemiplimab) is an FDA-approved monoclonal antibody used to treat advanced or metastatic squamous cell carcinoma (SCC) of the skin. It works by targeting and inhibiting the PD-1 receptor on T cells, enhancing the immune system's ability to recognize and attack cancer cells. Libtayo has shown significant efficacy in improving survival rates and overall response in patients with advanced SCC.

Keytruda (Pembrolizumab): Merck & Co

Keytruda (pembrolizumab) is an immune checkpoint inhibitor that has shown effectiveness in treating squamous cell carcinoma (SCC), particularly in cases of advanced or metastatic disease. By targeting the PD-1 pathway, Keytruda helps enhance the body's immune response against cancer cells, leading to improved survival rates in patients with SCC, especially those who have not responded to traditional therapies.

Opdivo (Nivolumab): Bristol-Myers Squibb/Ono Pharmaceuticals

Opdivo (Nivolumab) is an immune checkpoint inhibitor that has been approved for the treatment of advanced or metastatic squamous cell carcinoma (SCC), particularly in cases where traditional therapies have failed. By targeting the PD-1 receptor on immune cells, Opdivo helps to enhance the body's immune response against cancer cells, offering a promising option for improving survival outcomes in SCC patients.

Emerging Therapies in Squamous Cell Carcinoma Market

Xevinapant: Debiopharm/Merck

Xevinapant is an investigational drug being explored for the treatment of Squamous Cell Carcinoma (SCC). It is a first-in-class SMAC mimetic, designed to inhibit inhibitor of apoptosis proteins (IAPs), which are involved in promoting tumor survival. By targeting these proteins, Xevinapant aims to sensitize SCC cells to chemotherapy, enhancing treatment efficacy and potentially improving patient outcomes in advanced stages of SCC.

PRV 111: Privo Technologies

PRV-111 is an investigational drug currently being explored for the treatment of Squamous Cell Carcinoma (SCC). It is a novel compound designed to target specific molecular pathways involved in tumor growth and progression, offering potential benefits in treating advanced or resistant SCC. Clinical studies are ongoing to assess its efficacy and safety in SCC patients.

Detailed list of emerging therapies in Squamous Cell Carcinoma is provided in the final report…

Leading Companies in the Squamous Cell Carcinoma Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global Squamous Cell Carcinoma market, several leading companies are at the forefront of developing integrated platforms to enhance the management of Squamous Cell Carcinoma. Some of the major players include Regeneron Pharmaceuticals, Merck & Co, Bristol-Myers Squibb, Ono Pharmaceuticals, Debiopharm, Merck, Privo Technologies, Eli Lilly and Company, Genentech, BeiGene, and others. These companies are driving innovation in the Squamous Cell Carcinoma market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for Squamous Cell Carcinoma.

​In December 2024, The U.S. Food and Drug Administration has approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) blocking antibody, for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are ineligible for curative surgery or radiation.

Key Players in Squamous Cell Carcinoma Market:

The key players in the Squamous Cell Carcinoma market who are in different phases of developing different therapies are Regeneron Pharmaceuticals, Merck & Co, Bristol-Myers Squibb, Ono Pharmaceuticals, Debiopharm, Merck, Privo Technologies, Eli Lilly and Company, Genentech, BeiGene, and Others.

Regional Analysis:

The major markets for Squamous Cell Carcinoma include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for Squamous Cell Carcinoma while also representing the biggest market for its treatment. Novel treatments are emerging in the Squamous Cell Carcinoma (SCC) market, with advanced immunotherapies, targeted therapies, and molecular agents offering new approaches for more precise treatment. These innovations are designed to target tumor-specific genetic mutations, pro-inflammatory cytokines, and pathways involved in tumor progression. Among the most important ones are immune checkpoint inhibitors and monoclonal antibodies, which are being investigated for their ability to harness the immune system against SCC cells. Some of the most important ones are immune checkpoint inhibitors and monoclonal antibodies that look at the possibility of engaging the immune system against SCC cells. Among the newest ones that target specific epidermal growth factor receptors and other important molecular targets particularly useful for advanced SCCs while dramatically increasing efficacy and potentially avoiding systemic side effects are also in the works. Diagnostic application within the liquid biopsy, with the incorporation of NGS and molecular imaging approaches, aids in ameliorating early but accurate diagnosis of SCC, especially in the high-risk subset, and leads to individualized therapeutic designs. These devices enable clinicians to track tumor progression and treatment response better, ultimately leading to better patient outcomes.

Key factors driving the growth of the SCC market include increased investment in R&D, the rising number of novel therapies, and a greater focus on personalized medicine. Collaboration between pharmaceutical companies, diagnostic firms, and research institutions is accelerating the development of innovative treatment modalities. AI-driven diagnostics and telematic platforms further widen access to cutting-edge treatment even for unattended areas so that advanced care may be put within reach of a wider patient population. With innovation continuing in treatment and diagnostics alike, the North American and European markets continue to lead in SCC therapy, thus fostering the sustained growth of the global market.

Recent Developments in Squamous Cell Carcinoma Market:

• In January 2025, Regeneron Pharmaceuticals announced positive results from the Phase 3 C-POST trial, showing that adjuvant treatment with the PD-1 inhibitor Libtayo (cemiplimab) significantly improved disease-free survival (DFS) after surgery in individuals with cutaneous squamous cell carcinoma (CSCC) at high risk. The trial enrolled 415 patients with high-risk CSCC, who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary endpoint of DFS, defined as the time from randomization to the first documented disease recurrence or death from any cause, showed that Libtayo reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), based on the first prespecified interim analysis with a median follow-up of 24 months (range: 2-64 months).

Key information covered in the report

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Squamous Cell Carcinoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Squamous Cell Carcinoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current Squamous Cell Carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800